Synthesis and biological evaluation of new 4-carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors

被引:62
作者
Zarghi, Afshin [1 ]
Ghodsi, Razieh [1 ]
Azizi, Ebrahim [2 ]
Daraie, Bahram [3 ]
Hedayati, Mehdi [4 ]
Dadrass, Orkideh G. [5 ]
机构
[1] Shahid Beheshti Univ MC, Sch Pharm, Dept Pharmaceut Chem, Tehran, Iran
[2] Univ Tehran Med Sci, Sch Pharm, Dept Toxicol, Tehran, Iran
[3] Tarbiat Modares Univ, Dept Toxicol, Tehran, Iran
[4] Shahid Beheshti Univ MC, Endocrine Res Ctr, Tehran, Iran
[5] Azad Univ, Sch Pharm, Dept Pharmaceut Chem, Tehran, Iran
关键词
Cyclooxygenase-2; inhibition; 4-Carboxyl quinolines; SAR; COX-2; INHIBITORS; ROFECOXIB; MECHANISM; 4-(4'-METHYLSULFONYLPHENYL)-3-PHENYL-2(5H)-FURANONE; DISEASE; DESIGN; AGENTS; DRUGS;
D O I
10.1016/j.bmc.2009.05.084
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A group of 4-carboxyl quinoline derivatives possessing a methylsulfonyl COX-2 pharmacophore at the para position of the C-2 phenyl ring were designed and synthesized as selective COX-2 inhibitors. In vitro COX-1/COX-2 structure-activity relationships were determined by varying the substituents on the C-7 and C-8 quinoline ring. Among the 4-carboxyl quinolines, 7,8,9,10-tetrahydro-2-(4-(methyl sulfonyl) phenyl) benzo[h] quinoline-4-carboxylic acid (9e) was identified as potent and high selective COX-2 inhibitor (COX-2 IC(50) = 0.043 mu M; selectivity index > 513) that was more potent than the reference drug celecoxib (COX-2 IC(50) = 0.060 mu M; SI = 405). A molecular modeling study where 9e was docked in the binding site of COX-2 showed that the p-MeSO(2) substituent on the C-2 phenyl ring is oriented in the vicinity of the COX-2 secondary pocket (Arg513, Phe518 and Val523) and the carboxyl group can interact with Arg120. The structure activity data acquired indicate that the presence of lipophilic substituents on the C-7 and C-8 quinoline ring is important for COX-2 inhibitory activity. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5312 / 5317
页数:6
相关论文
共 26 条
[1]   Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial [J].
Aisen, PS ;
Schafer, KA ;
Grundman, M ;
Pfeiffer, E ;
Sano, M ;
Davis, KL ;
Farlow, MR ;
Jin, S ;
Thomas, RG ;
Thal, LJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21) :2819-2826
[2]  
[Anonymous], ANN REV PHARM TOXICO
[3]  
ANREICHIKOV YS, 1988, ZH ORG KHIM, V24, P875
[4]  
Aparicio Gallego G., 2007, CLIN T ONCOL, V9, P3305
[5]   POTENTIAL ANTITUMOR AGENTS .57. 2-PHENYLQUINOLINE-8-CARBOXAMIDES AS MINIMAL DNA-INTERCALATING ANTITUMOR AGENTS WITH INVIVO SOLID TUMOR-ACTIVITY [J].
ATWELL, GJ ;
BAGULEY, BC ;
DENNY, WA .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (02) :396-401
[6]   Cyclooxygenase inhibitors - current status and future prospects [J].
Dannhardt, G ;
Kiefer, W .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2001, 36 (02) :109-126
[7]   Adverse cardiovascular effects of the coxibs [J].
Dogné, JM ;
Supuran, CT ;
Pratico, D .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (07) :2251-2257
[8]   The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins [J].
Garavito, RM ;
DeWitt, DL .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 1999, 1441 (2-3) :278-287
[9]   Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents [J].
Kurumbail, RG ;
Stevens, AM ;
Gierse, JK ;
McDonald, JJ ;
Stegeman, RA ;
Pak, JY ;
Gildehaus, D ;
Miyashiro, JM ;
Penning, TD ;
Seibert, K ;
Isakson, PC ;
Stallings, WC .
NATURE, 1996, 384 (6610) :644-648
[10]   Differential binding mode of diverse cyclooxygenase inhibitors [J].
Llorens, O ;
Perez, JJ ;
Palomer, A ;
Mauleon, D .
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2002, 20 (05) :359-371